The Effect of Menstrual Cycle on the Results of Treadmill Exercise Test With High Sensitive Cardiac Troponin Levels After Exercise in Women

Sponsor
Istanbul Medeniyet University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05985980
Collaborator
(none)
40
1
7
5.7

Study Details

Study Description

Brief Summary

False positive results are commonly observed in women after exercise treadmill test (ETT). The effects of menstrual periodic changes on the results of exercise treadmill test in premenopausal women have not been clearly defined. Primary purpose of the study is to investigate the biological causes of false positive test results in the treadmill exercise test in premenopausal women. Estrogen is known to have direct vasodilatory effects on coronary arteries. Early and late follicular phases of the menstrual cycle are characterized by low and high estrogen levels, respectively. The Early Follicular Phase starts on the first day of the menstrual cycle and ends when oestradiol begins to increase. It is characterised by increasing LH and FSH and constant low levels of oestradiol. The late follicular phase starts with the increase in oestradiol and ends at its preovulatory peak. The hypothesis of the study is that ETT results will change at the early and late follicular phases in premenstrual women. Premenopausal women between the ages of 18-40, who apply to the cardiology outpatient clinics of Göztepe City Hospital with typical/atypical chest pain, and an indication for ETT will be included in the study. ETT will be performed in the early and late follicular phases of the menstrual cycle, separately.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Exercise Treadmill Test (ETT)

Detailed Description

Estrogen is known to have direct vasodilatory effects on coronary arteries. Early and late follicular phases of the menstrual cycle in premenopausal women are characterized by low and high estrogen levels, respectively. The Early Follicular Phase starts on the first day of the menstrual cycle and ends when oestradiol begins to increase. It is characterised by increasing LH and FSH and constant low levels of oestradiol. The late follicular phase starts with the increase in oestradiol and ends at its preovulatory peak. Premenopausal women (between the ages of 18-40), who apply to the cardiology outpatient clinics of Göztepe City Hospital with typical/atypical chest pain, and an indication for exercise treadmill test (ETT) will be included in the study. ETT will be performed in the early and late follicular phases of the menstrual cycle, separately.

Forty (40) patients who meet these conditions will be included in the study.

The menstrual cycle of the patient will be questioned in the screening interview. Premenopausal female patients between the ages of 18-40 who still have a regular menstrual cycles will be included in the study. Hormone levels including Estradiol III, follicle stimulating hormone (FSH), luteinizing hormone (LH), progesterone (Elecsys) will be measured to confirm the menstrual cycle before each ETT. ETT will be performed in the early and late follicular phases of the menstrual cycle, separately. Cardiac high sensitive troponin I (hs cTnI) (Roche) will be measured before and after ETT.

Primary end point will the ST/HR (heart rate) index (μV/bpm) in ETT. The ST/HR index (μV/bpm) is automatically generated by the General Electronic GE Healthcare T2100-ST Treadmill & CASE 6.73 Stress Test System.

The secondary endpoints will be the change in hs cTnI between the before and after ETT, maximal exercise capacity (METs score), ST/HR slope (μV/bpm), maximal horizontal or down slope ST segment depression (mm) with exercise. Secondary end points other than cTnI are automatically generated by the General Electronic GE Healthcare T2100-ST Treadmill & CASE 6.73 Stress Test System.

The null hypothesis is that there is no difference between in the ST/HR index (μV/bpm) between the menstrual phases. The power is calculated to prove the alternative hypothesis in which there is a 50 % difference between the ETT ST/HR index (μV/bpm). In a paired study sample, with type I error of 5 % and type II error of 20 %, the sample size is calculated as 34 patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Case-Crossover
Time Perspective:
Prospective
Official Title:
The Effect of Menstrual Cycle on the Results of Treadmill Exercise Test With High Sensitive Cardiac Troponin Levels After Exercise in Women
Actual Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Exercise test results will be grouped based on the menstrual cycle.

Positive exercise treadmill tests will be repeated at a different phase of menstrual cycle in premenopausal women (early versus late follicular phase).

Diagnostic Test: Exercise Treadmill Test (ETT)
Routinely ordered exercise treadmill test results will be reviewed in premenopausal women. ETT results and change in hs cTnI levels will be compared between the early and late follicular phases of menstrual cycle.

Outcome Measures

Primary Outcome Measures

  1. ST/HR index (μV/bpm) in ETT. [March-September 2023]

    The ST/HR index (μV/bpm) is automatically generated by the General Electronic GE Healthcare T2100-ST Treadmill & CASE 6.73 Stress Test System.

Secondary Outcome Measures

  1. change in the concentrations of high sensitive cardiac troponin I (ng/L) change before and after exercise [May-September 2023]

    hs cTnI will be measured by Roche kit.

  2. maximal exercise capacity (METs score) [May-September 2023]

    automatically generated by the General Electronic GE Healthcare T2100-ST Treadmill & CASE 6.73 Stress Test System.

  3. ST/HR slope (μV/bpm) [May-September 2023]

    automatically generated by the General Electronic GE Healthcare T2100-ST Treadmill & CASE 6.73 Stress Test System.

  4. maximal horizontal or down slope ST segment depression (mm) with exercise [May-September 2023]

    automatically generated by the General Electronic GE Healthcare T2100-ST Treadmill & CASE 6.73 Stress Test System.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Female
Inclusion Criteria:
  1. Patients with suspected ischemia in the exercise test

  2. Age is ≥18

  3. Female patients in the pre-menopausal period

  4. Patients who can understand and sign the consent form

Exclusion Criteria:
  1. Patients with history of coronary artery disease or myocardial infarction

  2. Secondary Hypertension, Uncontrolled hypertension

  3. Peripheral artery disease

  4. Patients with severe heart valve disease

  5. Cardiac arrhythmia

  6. Heart failure

  7. Cancer patients

  8. Severe kidney (stage ≥ 3 kidney failure) chronic liver disease

  9. Those who do not have the level of consciousness or mental capacity to understand and accept to participate in the study

  10. Pregnancy

  11. Those who use external hormonal therapy or drugs that will change the hormone level i.e. oral contraceptives

  12. Acute pericarditis, myocarditis or myopericarditis

  13. Sepsis, systemic infections

  14. Women with signs and symptoms of perimenopause or menopause.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Istanbul Medeniyet University Hospital, Goztepe Istanbul Turkey 34722

Sponsors and Collaborators

  • Istanbul Medeniyet University

Investigators

  • Study Director: Sukru Sadık Öner, MD PhD, Istanbul Medeniyet University City Hospital Goztepe

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mehmet Agirbasli MD, Medical Doctor, Professor of Cardiology, Istanbul Medeniyet University
ClinicalTrials.gov Identifier:
NCT05985980
Other Study ID Numbers:
  • 2023/0129
First Posted:
Aug 14, 2023
Last Update Posted:
Aug 14, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 14, 2023